Cardiovascular toxicities of cancer chemotherapy

Seminars in Oncology

Volumn 40, Issue 2, 2013, Pages 156-167

  Bonita, Raphael ^a   Pradhan, Rajesh ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; ATORVASTATIN; BEVACIZUMAB; BIOLOGICAL MARKER; BORTEZOMIB; CAPECITABINE; CYCLOPHOSPHAMIDE; DASATINIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; IMATINIB; LAPATINIB; MELPHALAN; MITOXANTRONE; PACLITAXEL; PERTUZUMAB; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAZOXANE; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; GASTROINTESTINAL TUMOR; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; LEUKEMIA; LOW DRUG DOSE; LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PERICARDITIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QT PROLONGATION; RISK FACTOR; SIDE EFFECT; SUDDEN DEATH; TORSADE DES POINTES;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; HYPERTENSION; MOLECULAR TARGETED THERAPY; NEOPLASMS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84875720671     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.01.004     Document Type: Article

References (91)

1. E. Lefrak, J. Pitha, S. Rosenheim, J.A. Gottlieb A clinicopathologic analysis of adriamycin cardiotoxicity Cancer 32 1973 302 314
2. M.S. Ewer, S.M. Lippman Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity J Clin Oncol 23 2005 2900 2902 (Pubitemid 46224107)
3. M. Jessup, W.T. Abraham, D.E. Casey 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of Heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 2009 1977 2016
4. R.B. Weiss The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19 1992 670 686 (Pubitemid 23004844)
5. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 2004 185 229 (Pubitemid 38720829)
6. P. Menna, O.G. Paz, M. Chello, E. Covino, E. Salvatorelli, G. Minotti Anthracycline cardiotoxicity Expert Opin Drug Saf 11 Suppl 1 2012 S21 S36
7. Y.L. Lyu, J.E. Kerrigan, C.P. Lin Topoisomerase II beta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane Cancer Res 67 2007 8839 8846 (Pubitemid 47437460)
8. K.A. Wouters, L.C. Kremer, T.L. Miller, E.H. Herman, S.E. Lipshultz Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies Br J Haematol 131 2005 561 578 (Pubitemid 43899624)
9. S.E. Lipshultz, J.A. Alvarez, R.E. Scully Anthracycline associated cardiotoxicity in survivors of childhood cancer Heart 94 2008 525 533 (Pubitemid 351441417)
10. A. Giantris, L. Abdurrahman, A. Hinkle, B. Asselin, S.E. Lipshultz Anthracycline-induced cardiotoxicity in children and young adults Crit Rev Oncol Hematol 27 1998 53 68 (Pubitemid 28275509)
11. J.P. Krischer, S. Epstein, D.D. Cuthbertson, A.M. Goorin, M.L. Epstein, S.E. Lipshultz Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience J Clin Oncol 15 1997 1544 1552 (Pubitemid 27167391)
12. D.D. Von Hoff, M.W. Layard, P. Basa Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 1979 710 717 (Pubitemid 10218041)
13. L.C. Kremer, E.C. van Dalen, M. Offringa, J. Ottenkamp, P.A. Voûte Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow up study J Clin Oncol 19 2001 191 196 (Pubitemid 32063496)
14. M.A. Grenier, S.E. Lipshultz Epidemiology of anthracycline cardiotoxicity in children and adults Semin Oncol 25 1998 72 85 (Pubitemid 28460388)
15. S.M. Swain, F.S. Whaley, M.S. Ewer Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer 97 2003 2869 2879 (Pubitemid 36605157)
16. L.A. Smith, V.R. Cornelius, C.J. Plummer Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials BMC Cancer 10 2010 337
17. L. Wojnowski, B. Kulle, M. Schirmer NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity Circulation 112 2005 3754 3762 (Pubitemid 43739516)
18. V.B. Pai, M.C. Nahata Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention Drug Saf 22 2000 263 302 (Pubitemid 30213944)
19. E.H. Romond, E.A. Perez, J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684 (Pubitemid 41464706)
20. J.J. McMurray, S. Adamopoulos, S.D. Anker ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur J Heart Fail 14 2012 803 869
21. T. Eschenhagen, T. Force, M.S. Ewer Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail 13 2011 1 10
22. A.L. Jones, M. Barlow, P.J. Barrett-Lee Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring Br J Cancer 100 2009 684 692
23. D. Bovelli, G. Plataniotis, F. Roila ESMO Guidelines Working Group Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines Ann Oncol 21 Suppl 5 2010 v277 v282
24. L.J. Steinherz, T. Graham, R. Hurwitz Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children's Cancer Study Group Pediatrics 89 1992 942 949
25. B. Marchandise, E. Schroeder, A. Bosly Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics Am Heart J 118 1989 92 98 (Pubitemid 19183582)
26. M.F. Stoddart, J. Seeger, N.E. Liddel, T.J. Hadley, D.M. Sullivan, J. Wupersmith Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans J Am Coll Cardiol 20 1992 62 69
27. R. Pudil, J.M. Horacek, A. Strasova, L. Jebavy, J. Vojacek Monitoring of the very early changes of left ventricular diastolic function in patients with acute leukemia treated with anthracyclines Exp Oncol 30 2008 160 162 (Pubitemid 351951396)
28. H. Sawaya, I.A. Sebag, J.C. Plana Early detection and prediction of cardiotoxicity in chemotherapy-treated patients Am J Cardiol 107 2011 1375 1380
29. J.T. Poterucha, S. Kutty, R.K. Lindquist, L. Li, B.W. Eidem Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction J Am Soc Echocardiogr 25 2012 733 740
30. H. Sawaya, I.A. Sebag, J.C. Plana Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes and trastuzumab Circ Cardiovasc Imaging 5 2012 596 603
31. J.V. Skrypniuk, D. Bailey, P.S. Cosgriff UK audit of left ventricular ejection fraction estimation from equilibrium ECG gated blood pool images Nucl Med Commun 26 2005 205 215 (Pubitemid 40411044)
32. R.G. Schwartz, W.B. Mckenzie, J. Alexander Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy Seven-year experience using serial radionuclide angiography Am J Med 82 1987 1109 1118
33. L.F. de Geus-Oei, A.M. Mavinkurve-Groothuis, L. Bellersen Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity J Nucl Med 52 2011 560 571
34. R. Wassmuth, S. Lentzsch, U. Erdbruegger Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging - a pilot study Am Heart J 141 2001 1007 1013 (Pubitemid 32477014)
35. D. Cardinale, M.T. Sandri Role of biomarkers in chemotherapy-induced cardiotoxicity Prog Cardiovasc Dis 53 2010 121 129
36. S.M. Swain, F.S. Whaley, M.C. Gerber Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer J Clin Oncol 15 1997 1318 1332 (Pubitemid 27167363)
37. M.L. Hensley, K.L. Hagerty, T. Kewalramani American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants J Clin Oncol 27 2009 127 145
38. N. Kalay, E. Basar, I. Ozdugru Protective effects of carvedilol against anthracycline-induced cardiomyopathy J Am Coll Cardiol 48 2006 2258 2262 (Pubitemid 44855419)
39. N.A. El-Shitany, O.A. Tolba, M.R. El-Shanshory, E.E. El-Hawary Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia J Card Fail 18 2012 607 613
40. Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol. Epub 2012 June 22
41. D. Cardinale, A. Colombo, M.T. Sandri Prevention of high dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 114 2006 2474 2481 (Pubitemid 44901520)
42. H. Nakamae, K. Tsumura, Y. Terada Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone Cancer 104 2005 2492 2498 (Pubitemid 41691573)
43. Z. Acar, A. Kale, M. Turgut Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy J Am Coll Cardiol 58 2011 988 989
44. R.C. Kukreja, F.N. Salloum, A. Das Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection J Am Coll Cardiol 59 2012 1921 1927
45. T.G. Neilan, D.S. Jassal, M.F. Scully Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression Eur Heart J 27 2006 1251 1256
46. D. Cardinale, A. Colombo, G. Lamantia Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy J Am Coll Cardiol 55 2010 213 220
47. J.S. Gottdiener, J.R. Appelbaum, V.J. Ferrans, A. Deisseroth, J. Ziegler Cardiotoxicity associated with high dose cyclophosphamide therapy Arch Intern Med 141 1981 758 763 (Pubitemid 11120879)
48. A.C. Braverman, J.H. Antin, M.T. Plappert, E.F. Cook, R.T. Lee Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens J Clin Oncol 9 1991 1215 1223
49. M.A. Goldberg, J.H. Antin, E.C. Guinan, J.M. Rappeport Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor Blood 68 1986 1114 1118 (Pubitemid 17186389)
50. E.T. Yeh, C.L. Bickford Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management J Am Coll Cardiol 53 2009 2231 2247
51. G. Curigliano, E.L. Mayer, H.J. Burstein, E.P. Winer, A. Goldhirsch Cardiac toxicity from systemic cancer therapy: a comprehensive review Prog Cardiovasc Dis 53 2010 94 104
52. E.A. Hawkes, A.F. Okines, C. Plummer, D. Cunningham Cardiotoxicity in patients treated with bevacizumab is potentially reversible J Clin Oncol 29 2011 e560 e562
53. M.H. Chen, R. Kerkela, T. Force Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics Circulation 118 2008 84 95
54. T.K. Choueiri, E.L. Mayer, Y. Je Congestive heart failure risk in patients with breast cancer treated with bevacizumab J Clin Oncol 29 2011 632 638
55. J.J. Monsuez, J.C. Charniot, N. Vignat, J.Y. Artigou Cardiac side-effects of cancer chemotherapy Int J Cardiol 144 2010 3 15
56. S.M. Ewer, M.S. Ewer Cardiotoxicity profile of trastuzumab Drug Saf 31 2008 459 467 (Pubitemid 351695459)
57. D. Lenihan, T. Suter, M. Brammer, C. Neate, G. Ross, J. Baselga Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab Ann Oncol 23 2012 791 800
58. E.A. Perez, M. Koehler, J. Byrne, A.J. Preston, E. Rappold, M.S. Ewer Cardiac safety of lapatinib pooled analysis of 3689 patients enrolled in clinical trials Mayo Clin Proc 83 2008 679 686 (Pubitemid 351810568)
59. R. Kerkelä, L. Grazette, R. Ullrich Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nat Med 12 2006 908 916 (Pubitemid 44175142)
60. G. Turrisi, F. Montagnani, C. Marinozzi, L. Bolognese, G. Fiorentini Congestive heart failure during imatinib mesylate treatment Int J Cardiol 145 2010 148 150
61. C.J. Richards, Y. Je, F.A. Schutz Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib J Clin Oncol 29 2011 3450 3456
62. H.Y. Fu, T. Minamino, O. Tsukamoto Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition Cardiovasc Res 79 2008 600 610
63. S. Bringhen, A. Larocca, D. Rossi Efficacy and safety of once-weekly bortezomib in multiple myeloma patients Blood 116 2010 4745 4753
64. E.K. Rowinsky, W.P. McGuire, T. Guarnieri, J.S. Fisherman, M.C. Christian, R.C. Donehower Cardiac disturbances during the administration of taxol J Clin Oncol 9 1991 1704 1712
65. T. Kamba, D.M. McDonald Mechanisms of adverse effects of anti-VEGF therapy for cancer Br J Cancer 96 2007 1788 1795 (Pubitemid 46912024)
66. V. Ranpura, S. Hapani, J. Chuang, S. Wu Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials Acta Oncol 49 2010 287 297
67. M.J. Moore, D. Goldstein, J. Hamm Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 2007 1960 1966 (Pubitemid 46972777)
68. Y. Arima, S. Oshima, K. Noda Sorafenib-induced acute myocardial infarction due to coronary artery spasm J Cardiol 54 2009 512 515
69. I. Porto, A. Leo, L. Miele, M. Pompili, R. Landolfi, F. Crea A case of variant angina in a patient under chronic treatment with sorafenib Nat Rev Clin Oncol 7 2010 476 480
70. T. Naib, R.M. Steingart, C.L. Chen Sorafenib-associated multivessel coronary artery vasospasm Herz 36 2011 348 351
71. M. Jain, R.R. Townsend Chemotherapy agents and hypertension: a focus on angiogenesis blockade Curr Hypertens Rep 9 2007 320 328 (Pubitemid 47377031)
72. B. Nazer, B.D. Humphreys, J. Moslehi Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension Circulation 124 2011 1687 1691
73. M.M. An, Z. Zou, H. Shen Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis Eur J Clin Pharmacol 66 2010 813 821
74. L.G. Paz-Ares, B. Biesma, D. Heigener Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer J Clin Oncol 30 2012 3084 3092
75. J. Beck, G. Procopio, E. Bajetta Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings Ann Oncol 22 2011 1812 1823
76. S. Wu, J.J. Chen, A. Kudelka, J. Lu, X. Zhu Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis Lancet Oncol 9 2008 117 123
77. M.L. Maitland, K.E. Kasza, T. Karrison Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment Clin Cancer Res 15 2009 6250 6257
78. B.I. Rini, B. Escudier, P. Tomczak Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
79. X. Zhu, K. Stergiopoulos, S. Wu Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis Acta Oncol 48 2009 9 17
80. C.N. Sternberg, I.D. Davis, J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
81. R.S. Herbst, Y. Sun, W.E. Eberhardt Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial Lancet Oncol 11 2010 619 626
82. R.H. de Boer, Ó. Arrieta, C.H. Yang Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial J Clin Oncol 29 2011 106 174
83. R.B. Natale, S. Thongprasert, F.A. Greco Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer J Clin Oncol 29 2011 1059 1066
84. S.A. Wells Jr, B.G. Robinson, R.F. Gagel Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial J Clin Oncol 30 2012 134 141
85. J.S. Lee, V. Hirsh, K. Park Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR) J Clin Oncol 30 2012 1114 1121
86. M.L. Maitland, G.L. Bakris, H.R. Black Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors J Natl Cancer Inst 102 2010 596 604
87. R. Goodwin, K. Ding, L. Seymour Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24 Ann Oncol 21 2010 2220 2226
88. S.L. Soignet, S.R. Frankel, D. Douer United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia J Clin Oncol 19 2001 3852 3860 (Pubitemid 32880064)
89. W. Rasheed, B. Flaim, J. Seymour Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia Leuk Res 33 2009 861 864
90. D. Montani, E. Bergot, S. Gunther Pulmonary arterial hypertension in patients treated by dasatinib Circulation 125 2012 2128 2137
91. S.S. Pullamsetti, E.M. Berghausen, S. Dabral Role of Src tyrosine kinases in experimental pulmonary hypertension Arterioscler Thromb Vasc Biol 32 2012 1354 1365